However, since Richard A Morgan first reported a lethal case in which a patient with colon cancer metastatic to the lungs and liver was treated with a dose of 1010 CART-HER2 cells, resulting in uncontrollable acute respiratory distress and subsequent death (Morgan RA et al., 2010), the investigation of CART cell immunotherapy targeting overexpressed HER2 antigen had to be suspended for the safety concern until Nabil Ahmed proved that HER2-specific CART cells were well tolerated with no dose-limiting toxicity in 19 patients with HER2-positive sarcoma (Ahmed N et al., 2015). Here, ERBB2 is linked to malignant colon neoplasm.